A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer

RecruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

March 31, 2031

Study Completion Date

August 31, 2031

Conditions

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Low-volume Metastasis

Interventions

DRUG

Darolutamide (BAY1841788) + docetaxel + ADT

Follow clinical practice/administration. ADT=androgen deprivation therapy.

Trial Locations (1)

RECRUITING

Many locations, Multiple Locations